News | News By Subject | News by Disease News By Date | Search News

Hepatitis-C News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
FDA Green Lights Gilead (GILD)'s Vosevi, With a Black Box Warning Attached     7/20/2017
The Single Best Hep C Drug Stock to Buy in 2017—Hint, It's Not Gilead (GILD)     6/12/2017
Why the Government Should Pay $156 Billion to Own Gilead (GILD)     1/18/2017
Gilead (GILD) CEO Remorseful Over Sovaldi's $1,000 Per Pill Price Tag     12/9/2016
Gilead (GILD) Drops Another Bombshell, Will Shift R&D Cash Away From Hep C     11/7/2016
The $40 Billion NASH Market and the 3 Biotechs That Stand to Profit From it     11/2/2016
After Hep C Flop, Has Vertex (VRTX) Learned From Its Past Mistakes?     10/18/2016
Achillion (ACHN), Johnson & Johnson (JNJ)'s Hep C Candidate Scores a 100% Cure Rate in Phase IIa Trial     9/9/2016
FDA Green Lights AbbVie (ABBV) Once-Daily Viekira XR for Hepatitis C     7/26/2016
Gilead (GILD)'s Strategy for New Hep C Drug Epclusa     7/7/2016
Regulus (RGLS) Shares Crumble As FDA Puts Hep C Treatment on Hold     6/28/2016
Gilead (GILD)'s Plan to Dominate the Hepatitis C Market     6/27/2016
Two Upstarts that Could Dislodge Gilead (GILD)'s Hold on the Hepatitis C Market     6/22/2016
Federal Judge Reopens Gilead (GILD) Case Amid Allegations Former Merck & Co. (MRK) Scientist Lied     5/3/2016
AbbVie (ABBV)'s New Hep C Regimen Shows High Cure Rates in Mid-Stage Trial     4/18/2016

News from Around the Web
When It Comes To Abusive Drug Pricing, Don't Confuse Shkreli With Hep C Drugs     7/19/2017
3 Numbers That Make Gilead (GILD) Look Cheaper Than It Really Is     3/17/2017
New Report Questions the Safety of Gilead (GILD)'s Pricey Hep C Drugs     1/26/2017
Gilead (GILD)'s Hep C Med the Most Costly for Medicare, Medicaid in 2015     11/15/2016
University of Pennsylvania Study Looks To Speed Transplants With Hepatitis C-Infected Kidneys     10/28/2016
The Lab Breakthrough And The Two Men Behind Today’s Pricey Hepatitis C Cures     9/13/2016
Vietnam Vets Blame "Jet Guns" For Their Hepatitis C     2/15/2016
One-Step Test For Hepatitis C Virus Infection Developed, University of California, Irvine Health Researchers Reveal     11/16/2015
Gilead (GILD) Beats AbbVie (ABBV) Again     9/22/2015
China Rejects Patent Linked To Gilead (GILD) Hepatitis C Drug     6/22/2015
Gilead (GILD) Holds Cash Overseas to Save Billions on Taxes     2/27/2015
Gilead Sciences, Inc. (GILD)'s $1,000-A-Pill Hepatitis C Drug May Make Financial Sense For Prisons     10/21/2014
Gilead Sciences, Inc. (GILD) Looks To Erase Bristol-Myers Squibb Company (BMY)'s Early Hep C Lead     9/30/2014
What Happened At BioPharm America 2014?     9/24/2014
Hepatitis C Could Become A Rare Disease By 2036, University of Pittsburgh Reveals     8/5/2014

Press Releases
Enanta Pharmaceuticals, Inc. Announces That AbbVie (ABBV) Receives CHMP Positive Opinion For MAVIRET (Glecaprevir/Pibrentasvir) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)     6/23/2017
European CHMP Adopts Positive Opinion For Gilead (GILD)’s Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir) For The Treatment Of All Chronic Hepatitis C Genotypes     6/23/2017
AbbVie (ABBV) Receives CHMP Positive Opinion For MAVIRET (Glecaprevir/Pibrentasvir) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)     6/23/2017
CDC Release: New Hepatitis C Infections Nearly Tripled Over Five Years     5/15/2017
Digestive Disease Week Release: Study Identifies Genetic Markers That Predict Which Patients With Hepatitis C And Cirrhosis Will Improve With Treatment     5/9/2017
Merck & Co. (MRK) Announces New Phase II Data On Investigational Triple Combination Therapy MK-3682B For Chronic Hepatitis C     4/24/2017
Gilead (GILD) Announces Scientific Presentations Demonstrating Efficacy Of Harvoni (Ledipasvir/Sofosbuvir) In Special Patient Populations With HCV Infection     4/24/2017
Achillion (ACHN) Announces Additional Phase II Results Including 100% SVR24 For Genotype 1 HCV After 6-Weeks Of Once Daily JNJ-4178     4/24/2017
Inovio Pharma (INO) Initiates Phase II Efficacy Trial With VGX-3100 For HPV-Related Vulvar Pre-Cancers     4/24/2017
Real-World Observational Study In The U.S. Veterans Affairs System Evaluating Use Of Merck & Co. (MRK)’s ZEPATIER (Elbasvir And Grazoprevir) Shows High Sustained Virologic Response Rates In Patients With Chronic Hepatitis C     4/21/2017
The Medicines Patent Pool And Pharco Pharmaceuticals Sign License For Promising Hepatitis C Drug Candidate Ravidasvir     4/21/2017
AbbVie (ABBV)'s Investigational, Pan-Genotypic, Ribavirin-Free Regimen Of Glecaprevir/Pibrentasvir (G/P) Achieved 99 Percent SVR(12) Rate In Chronic Hepatitis C Patients With Compensated Cirrhosis     4/20/2017
Gilead (GILD) Release: FDA Approves New Indications For Harvoni And Sovaldi In Pediatric Patients 12 Years And Older With Chronic Hepatitis C Infection     4/7/2017
Prime Therapeutics Study Finds 97 Percent Of Hepatitis C Patients Cured With Harvoni Treatment     3/21/2017
AbbVie (ABBV) Granted Priority Review In Japan For Its Investigational Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of All Major Genotypes Of Chronic Hepatitis C     3/14/2017

//-->